Your browser doesn't support javascript.
loading
A smart devices based secondary prevention program for cerebrovascular disease patients.
Motolese, Francesco; Capone, Fioravante; Magliozzi, Alessandro; Vico, Carlo; Iaccarino, Gianmarco; Falato, Emma; Pilato, Fabio; Di Lazzaro, Vincenzo.
Afiliação
  • Motolese F; Department of Medicine and Surgery, Unit of Neurology, Neurophysiology, Neurobiology and Psichiatry, Università Campus Bio-Medico di Roma, Roma, Italy.
  • Capone F; Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy.
  • Magliozzi A; Department of Medicine and Surgery, Unit of Neurology, Neurophysiology, Neurobiology and Psichiatry, Università Campus Bio-Medico di Roma, Roma, Italy.
  • Vico C; Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy.
  • Iaccarino G; Department of Medicine and Surgery, Unit of Neurology, Neurophysiology, Neurobiology and Psichiatry, Università Campus Bio-Medico di Roma, Roma, Italy.
  • Falato E; Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy.
  • Pilato F; Department of Medicine and Surgery, Unit of Neurology, Neurophysiology, Neurobiology and Psichiatry, Università Campus Bio-Medico di Roma, Roma, Italy.
  • Di Lazzaro V; Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy.
Front Neurol ; 14: 1176744, 2023.
Article em En | MEDLINE | ID: mdl-37333012
ABSTRACT

Background:

Commercially available health devices are gaining momentum and represent a great opportunity for monitoring patients for prolonged periods. This study aimed at testing the feasibility of a smart device-based secondary prevention program in a cohort of patients with cryptogenic stroke.

Methods:

In this proof-of-principle study, patients with non-disabling ischemic stroke and transient ischemic attacks (TIA) in the subacute phase were provided with a smartwatch and smart devices to monitor several parameters - i.e., oxygen saturation, blood pressure, steps a day, heart rate and heart rate variability - for a 4-week period (watch group). This group was compared with a standard-of-care group. Our primary endpoint was the compliance with the use of smart devices that was evaluated as the number of measures performed during the observation period.

Results:

In total, 161 patients were recruited, 87 in the WATCH group and 74 in the control group. In the WATCH group, more than 90% of patients recorded the ECG at least once a day. In total, 5,335 ECGs were recorded during the study. The median blood pressure value was 132/78 mmHg and the median oxygen saturation value was 97%. From a clinical standpoint, although not statistically significant, nine atrial fibrillation episodes (10.3%) in the WATCH group vs. 3 (4%) in the control group were detected.

Conclusion:

Our study suggests that prevention programs for cerebrovascular disease may benefit from the implementation of new technologies.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Idioma: En Revista: Front Neurol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Idioma: En Revista: Front Neurol Ano de publicação: 2023 Tipo de documento: Article